Monocytes mediate HIV neuropathogenesis: Mechanisms that contribute to HIV associated neurocognitive disorders

Current HIV Research

Volumn 12, Issue 2, 2014, Pages 85-96

  Williams, Dionna W ^a   Veenstra, Mike ^a   Gaskill, Peter J ^a   Morgello, Susan ^b   Calderon, Tina M ^a   Berman, Joan W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

BBB; Chemokine; HIV; Neuroinflammation

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE A; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; FC RECEPTOR;

ANTIVIRAL THERAPY; BLOOD BRAIN BARRIER; CELL HETEROGENEITY; CELL MIGRATION; DISEASE CARRIER; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; REVIEW; METABOLISM; PATHOPHYSIOLOGY;

ANTIGENS, CD14; HIV INFECTIONS; HUMANS; MACROPHAGES; MONOCYTES; RECEPTORS, IGG;

EID: 84905656041     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666140526114526     Document Type: Review

References (183)

1. Brew BJ, Gray L, Lewin S, Churchill M. Is specific HIV eradication from the brain possible or needed? Expert Opinion on Biological Therapy 2013; 13: 403-9.
2. Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS ONE 2012; 7: e49272.
3. Ances B, Ellis R. Dementia and Neurocognitive Disorders Due to HIV-1 Infection. Seminars in Neurology 2007; 27: 086-92.
4. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 2005; 12: 878-92.
5. Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of Neurovirology 2011; 17: 3-16.
6. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest 1986; 77: 1712-5.
7. Figdor C, Bont W, Touw I, de Roos J, Roosnek E, de Vries J. Isolation of functionally different human monocytes by counterflow centrifugation elutriation. Blood 1982; 60: 46-53.
8. Yasaka T, Mantich N, Boxer L, Baehner R. Functions of human monocyte and lymphocyte subsets obtained by countercurrent centrifugal elutriation: differing functional capacities of human monocyte subsets. The Journal of Immunology 1981; 127: 1515-8.
9. Passlick B, Flieger D, Ziegler-Heitbrock H. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-34.
10. Williams DW, Eugenin EA, Calderon TM, Berman JW. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. Journal of Leukocyte Biology 2012; 91: 401-15.
11. Buckner CM, Calderon TM, Willams DW, Belbin TJ, Berman JW. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: Implications for NeuroAIDS. Cell Immunol 2011; 267: 109-23.
12. Clarkson SB, Ory PA. Developmentally regulated IgG Fc receptors on cultured human monocytes. The Journal of Experimental Medicine 1988; 167: 408-20.
13. Ziegler-Heitbrock HWL, Fingerle G, Ströbel M, Schraut W, Stelter F, Schütt C, et al. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. European Journal of Immunology 1993; 23: 2053-8.
14. Zawada AM, Rogacev KS, Rotter B, Winter P, Marell R-R, Fliser D, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-e61.
15. Wong KL, Tai JJ-Y, Wong W-C, Han H, Sem X, Yeap W-H, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011; 118: e16-e31.
16. Appleby LJ, Nausch N, Midzi N, Mduluza T, Allen JE, Mutapi F. Sources of heterogeneity in human monocyte subsets. Immunology Letters 2013.
17. Ancuta P, Liu K-Y, Misra V, Wacleche V, Gosselin A, Zhou X, et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16-monocyte subsets. BMC Genomics 2009; 10: 403.
18. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
19. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Frontiers in immunology 2013; 4.
20. Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, et al. Phase I Trial of Recombinant Macrophage Colony-stimulating Factor and Recombinant γ-Interferon: Toxicity, Monocytosis, and Clinical Effects. Cancer Research 1994; 54: 4084-90.
21. Korkosz M, Bukowska-Strakova K, Sadis S, Grodzicki T, Siedlar M. Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14++CD16+/CD14+CD16++) monocytes in rheumatoid arthritis patient. Blood 2012; 119: 5329-30.
22. Haskill S, Johnson C, Eierman D, Becker S, Warren K. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. The Journal of Immunology 1988; 140: 1690-4.
23. Shaw RJ, Doherty DE, Ritter AG, Benedict SH, Clark RA. Adherence-dependent increase in human monocyte PDGF(B) mRNA is associated with increases in c-fos, c-jun, and EGR2 mRNA. The Journal of Cell Biology 1990; 111: 2139-48.
24. van Furth R, Cohn ZA. The Origin and Kinetics of Mononuclear Phagocytes. The Journal of Experimental Medicine 1968; 128: 415-35.
25. Williams DW, Calderon TM, Lopez L, Carvallo-Torres L, Gaskill PJ, Eugenin EA, et al. Mechanisms of HIV Entry into the CNS: Increased Sensitivity of HIV Infected CD14+CD16+ Monocytes to CCL2 and Key Roles of CCR2, JAM-A, and ALCAM in Diapedesis. PLoS ONE 2013; 8: e69270.
26. Allen JB, Wong HL, Guyre PM, Simon GL, Wahl SM. Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta. J Clin Invest 1991; 87: 1773-9.
27. Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 1995; 25: 3418-24.
28. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet 1997; 349: 692-5.
29. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007; 178: 6581-9.
30. Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, Dunne A, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001; 15: 17-22.
31. Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, et al. Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14 Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy. Journal of virology 2002; 76: 707-16.
32. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. The New England journal of medicine 1999; 340: 1614-22.
33. Crowe SM, Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. Journal of Leukocyte Biology 2000; 68: 345-50.
34. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999) 2000; 23: 114-9.
35. Llewellyn N, Zioni R, Zhu H, Andrus T, Xu Y, Corey L, et al. Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. Journal of Leukocyte Biology 2006; 80: 1118-26.
36. Patterson BK, Mosiman VL, Cantarero L, Furtado M, Bhattacharya M, Goolsby C. Detection of HIV-RNA-positive monocytes in peripheral blood of HIV-positive patients by simultaneous flow cytometric analysis of intracellular HIV RNA and cellular immunophenotype. Cytometry (New York, NY) 1998; 31: 265-74.
37. Ancuta P, Kunstman K, Autissier P, Zaman T, Stone D, Wolinsky S, et al. CD16+ monocytes exposed to HIV promote highly efficient viral replication upon differentiation into macrophages and interaction with T cells. Virology 2006; 344: 267-76.
38. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, et al. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology 2009; 72: 992-8.
39. Narayan O, Kennedy-Stoskopf S, Sheffer D, Griffin DE, Clements JE. Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages. Infect Immun 1983; 41: 67-73.
40. Gendelman HE, Narayan O, Kennedy-Stoskopf S, Kennedy PG, Ghotbi Z, Clements JE, et al. Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol 1986; 58: 67-74.
41. Naif HM, Li S, Alali M, Sloane A, Wu L, Kelly M, et al. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998; 72: 830-6.
42. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM. Expression of CCR5 Increases during Monocyte Differentiation and Directly Mediates Macrophage Susceptibility to Infection by Human Immunodeficiency Virus Type 1. J Virol 1998; 72: 4962-9.
43. Coquillard G, Patterson BK. Determination of Hepatitis C Virus-Infected, Monocyte Lineage Reservoirs in Individuals With or Without HIV Coinfection. Journal of Infectious Diseases 2009; 200: 947-54.
44. Shieh MT. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. The Journal of Cell Biology 1992; 116: 1273-81.
45. Saphire ACS, Bobardt MD, Zhang Z, David G, Gallay PA. Syndecans Serve as Attachment Receptors for Human Immunodeficiency Virus Type 1 on Macrophages. Journal of virology 2001; 75: 9187-200.
46. Liu J. Cell surface heparan sulfate and its roles in assisting viral infections. Medicinal research reviews 2002; 22: 1-25.
47. Bacsa S, Karasneh G, Dosa S, Liu J, Valyi-Nagy T, Shukla D. Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. Journal of general virology 2011; 92: 733-43.
48. Bozzini S, Falcone V, Conaldi PG, Visai L, Biancone L, Dolei A, et al. Heparin-binding domain of human fibronectin binds HIV-1 gp120/160 and reduces virus infectivity. J Med Virol 1998; 54: 44-53.
49. Greco G, Pal S, Pasqualini R, Schnapp LM. Matrix Fibronectin Increases HIV Stability and Infectivity. The Journal of Immunology 2002; 168: 5722-9.
50. Crowe S, Mills J, McGrath M. Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocyte/macrophages. AIDS Research and Human Retroviruses 1987; 3: 135.
51. Olivetta E, Federico M. HIV-1 Nef protects human-monocyte-derived macrophages from HIV-1-induced apoptosis. Experimental Cell Research 2006; 312: 890-900.
52. Giri MS, Nebozyhn M, Raymond A, Gekonge B, Hancock A, Creer S, et al. Circulating Monocytes in HIV-1-Infected Viremic Subjects Exhibit an Antiapoptosis Gene Signature and Virus-and Host-Mediated Apoptosis Resistance. The Journal of Immunology 2009; 182: 4459-70.
53. Cummins N, Badley A. Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV. Cellular and Molecular Life Sciences 2012: 1-9.
54. Reynoso R, Wieser M, Ojeda D, Bönisch M, Kühnel H, Bolcic F, et al. HIV-1 Induces Telomerase Activity in Monocyte-Derived Macrophages, Possibly Safeguarding One of Its Reservoirs. Journal of virology 2012; 86: 10327-37.
55. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, et al. Perivascular Macrophages Are the Primary Cell Type Productively Infected by Simian Immunodeficiency Virus in the Brains of Macaques: Implications for the Neuropathogenesis of AIDS. The Journal of Experimental Medicine 2001; 193: 905-16.
56. Lassmann H, Schmied M, Vass K, Hickey WF. Bone marrow derived elements and resident microglia in brain inflammation. Glia 1993; 7: 19-24.
57. Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001; 7: 528-41.
58. Pulliam L, Sun B, Rempel H. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. Journal of Neuroimmunology 2004; 157: 93-8.
59. Fischer-Smith T, Croul S, Adeniyi A, Rybicka K, Morgello S, Khalili K, et al. Macrophage/Microglial Accumulation and Proliferating Cell Nuclear Antigen Expression in the Central Nervous System in Human Immunodeficiency Virus Encephalopathy. Am J Pathol 2004; 164: 2089-99.
60. Eugenin EA, Berman JW. Gap Junctions Mediate Human Immunodeficiency Virus-Bystander Killing in Astrocytes. The Journal of Neuroscience 2007; 27: 12844-50.
61. Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS (London) 1999; 13: 1-22.
62. Spudich S, González-Scarano F. HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment. Cold Spring Harbor Perspectives in Medicine 2012; 2.
63. Shapshak P, Kangueane P, Fujimura RK, Commins D, Chiappelli F, Singer E, et al. Editorial NeuroAIDS review. AIDS 2011; 25: 123-41.
64. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: The effects of HIV-1 on the blood-brain barrier. Brain Res 2011; 1399: 96-115.
65. Liner K, Ro M, Robertson K. HIV, Antiretroviral Therapies, and the Brain. Current HIV/AIDS Reports 2010; 7: 85-91.
66. Edén A, Price Richard W, Spudich S, Fuchs D, Hagberg L, Gisslén M. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. The Journal of Infectious Diseases 2007; 196: 1779-83.
67. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011; 25: 625-33.
68. Roc AC, Ances BM, Chawla S, Korczykowski M, Wolf RL, Kolson DL, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Archives of Neurology 2007; 64: 1249.
69. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002; 16: 2145-9.
70. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999) 2008; 47: 168.
71. Desplats P, Dumaop W, Smith D, Adame A, Everall I, Letendre S, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013; 80: 1415-23.
72. Pulliam L, Rempel H, Sun B, Abadjian L, Calosing C, Meyerhoff DJ. A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations. AIDS 2011; 25: 1721-6.
73. Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of Neurovirology 2009; 15: 360-70.
74. Cherner M, Masliah E, Ellis R, Marcotte T, Moore D, Grant I, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002; 59: 1563-7.
75. Cherner M, Cysique L, Heaton RK, Marcotte TD, Ellis RJ, Masliah E, et al. Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. Journal of Neurovirology 2007; 13: 23-8.
76. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, et al. The National NeuroAIDS Tissue Consortium Brain Gene Array: Two Types of HIV-Associated Neurocognitive Impairment. PLoS ONE 2012; 7: e46178.
77. Borjabad A, Morgello S, Chao W, Kim S-Y, Brooks AI, Murray J, et al. Significant Effects of Antiretroviral Therapy on Global Gene Expression in Brain Tissues of Patients with HIV-1-Associated Neurocognitive Disorders. PLoS Pathog 2011; 7: e1002213.
78. Yadav A, Collman RG. CNS Inflammation and Macrophage/Microglial Biology Associated with HIV-1 Infection. Journal of Neuroimmune Pharmacology 2009; 4: 430-47.
79. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proceedings of the National Academy of Sciences 1998; 95: 3117-21.
80. Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, et al. Monocyte Activation Markers in Cerebrospinal Fluid Associated With Impaired Neurocognitive Testing in Advanced HIV Infection. Journal of Acquired Immune Deficiency Syndromes 2012; 60: 234-43. 10.1097/QAI.0b013e318256f3bc.
81. Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antiviral therapy 2004; 9: 431-40.
82. Letendre S, Zheng J, Kaul M, Yiannoutsos C, Ellis R, Taylor M, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. Journal of Neurovirology 2011; 17: 63-9.
83. Zaritsky LA, Gama L, Clements JE. Canonical Type I IFN Signaling in Simian Immunodeficiency Virus-Infected Macrophages Is Disrupted by Astrocyte-Secreted CCL2. The Journal of Immunology 2012; 188: 3876-85.
84. Jaeger LB, Nath A. Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis. Disease Models & Mechanisms 2012; 5: 313-22.
85. Cowley D, Gray L, Wesselingh S, Gorry P, Churchill M. Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. Journal of Neurovirology 2011; 17: 70-81.
86. Li W, Li G, Steiner J, Nath A. Role of Tat Protein in HIV Neuropathogenesis. Neurotoxicity research 2009; 16: 205-20.
87. Weiss JM, Nath A, Major EO, Berman JW. HIV-1 Tat Induces Monocyte Chemoattractant Protein-1-Mediated Monocyte Transmigration Across a Model of the Human Blood-Brain Barrier and Up-Regulates CCR5 Expression on Human Monocytes. The Journal of Immunology 1999; 163: 2953-9.
88. Bethel-Brown C, Yao H, Callen S, Lee YH, Dash PK, Kumar A, et al. HIV-1 Tat-Mediated Induction of Platelet-Derived Growth Factor in Astrocytes: Role of Early Growth Response Gene 1. The Journal of Immunology 2011; 186: 4119-29.
89. Aversa TG, Yu KO, Berman JW. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. Journal of Neurovirology 2004; 10: 86-97.
90. Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 2003; 85: 1299-311.
91. Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik Parsadaniantz S. Current status of chemokines in the adult CNS. Progress in Neurobiology 2013; 104: 67-92.
92. Li M, Ransohoff RM. Multiple roles of chemokine CXCL12 in the central nervous system: A migration from immunology to neurobiology. Progress in Neurobiology 2008; 84: 116-31.
93. Carbajal KS, Schaumburg C, Strieter R, Kane J, Lane TE. Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis. Proceedings of the National Academy of Sciences 2010; 107: 11068-73.
94. Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, Raine CS, et al. A role for CXCL12 (SDF-1α) in the pathogenesis of multiple sclerosis: Regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. Journal of Neuroimmunology 2006; 177: 27-39.
95. Man S, Tucky B, Cotleur A, Drazba J, Takeshita Y, Ransohoff RM. CXCL12-Induced Monocyte-Endothelial Interactions Promote Lymphocyte Transmigration Across an in Vitro Blood-Brain Barrier. Science Translational Medicine 2012; 4: 119ra14.
96. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. Journal of Neuroimmunology 1998; 86: 20-9.
97. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Seminars in Immunology 2003; 15: 23-32.
98. Thelen M, Thelen S. CXCR7, CXCR4 and CXCL12: An eccentric trio? Journal of Neuroimmunology 2008; 198: 9-13.
99. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009; 113: 6085-93.
100. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, et al. Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000; 6: S82-5.
101. Eugenin EA, Berman JW. Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003; 29: 351-61.
102. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 2006; 26: 1098-106.
103. Langford D, Sanders VJ, Mallory M, Kaul M, Masliah E. Expression of stromal cell-derived factor 1α protein in HIV encephalitis. Journal of Neuroimmunology 2002; 127: 115-26.
104. Rostasy K, Egles C, Chauhan A, Kneissl M, Bahrani P, Yiannoutsos C, et al. SDF-1[alpha] Is Expressed in Astrocytes and Neurons in the AIDS Dementia Complex: An In Vivo and In Vitro Study. Journal of Neuropathology & Experimental Neurology 2003; 62: 617-26.
105. Peng H, Erdmann N, Whitney N, Dou H, Gorantla S, Gendelman HE, et al. HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1β. Glia 2006; 54: 619-29.
106. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, et al. Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection. Journal of Infectious Diseases 2012.
107. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42: 1736-9.
108. Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. Journal of Infectious Diseases 2013.
109. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature (London) 1987; 325: 253-7.
110. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
111. Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD. Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells. Brain Research 1993; 625: 238-43.
112. Gloor SM, Wachtel M, Bolliger MF, Ishihara H, Landmann R, Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res Brain Res Rev 2001; 36: 258-64.
113. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13.
114. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascular Pharmacology 2002; 38: 323-37.
115. Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Seminars in Immunology 1999; 11: 125-37.
116. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. Journal of neuroscience research 1991; 28: 254-60.
117. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B. Review: Leucocyte-endothelial cell crosstalk at the blood-brain barrier: A prerequisite for successful immune cell entry to the brain. Neuropathology and Applied Neurobiology 2011; 37: 24-39.
118. Muller WA. Mechanisms of Leukocyte Transendothelial Migration. Annual Review of Pathology: Mechanisms of Disease 2011; 6: 323-44.
119. Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunological Reviews 2012; 248: 228-39.
120. Roberts TK, Buckner CM, Berman JW. Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS. Front Biosci 2010; 15: 478-536.
121. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003; 24: 327-34.
122. Schmidt EP, Lee WL, Zemans RL, Yamashita C, Downey GP. On, Around, and Through: Neutrophil-Endothelial Interactions in Innate Immunity. Physiology 2011; 26: 334-47.
123. Millan J, Hewlett L, Glyn M, Toomre D, Clark P, Ridley AJ. Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola-and F-actin-rich domains. Nat Cell Biol 2006; 8: 113-23.
124. Muller WA. Getting Leukocytes to the Site of Inflammation. Veterinary Pathology Online 2013; 50: 7-22.
125. Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J Cereb Blood Flow Metab 2005; 26: 797-810.
126. Stamatovic SM. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. Journal of cerebral blood flow and metabolism 2005; 25: 593-606.
127. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV. Protein Kinase Cα-RhoA Cross-talk in CCL2-induced Alterations in Brain Endothelial Permeability. Journal of Biological Chemistry 2006; 281: 8379-88.
128. Luissint A-C, Artus C, Glacial F, Ganeshamoorthy K, Couraud P-O. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids and Barriers of the CNS 2012; 9: 1-12.
129. Stamatovic SM, Sladojevic N, Keep RF, Andjelkovic AV. Relocalization of junctional adhesion molecule-A during inflammatory stimulation of brain endothelial cells. Molecular and Cellular Biology 2012.
130. Roberts TK, Eugenin EA, Lopez L, Romero IA, Weksler BB, Couraud P-O, et al. CCL2 disrupts the adherens junction: implications for neuroinflammation. Lab Invest 2012; 92: 1213-33.
131. Xu R, Feng X, Xie X, Zhang J, Wu D, Xu L. HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9. Brain Research 2012; 1436: 13-9.
132. Louboutin J-P, Strayer DS. Blood-Brain Barrier Abnormalities Caused by HIV-1 gp120: Mechanistic and Therapeutic Implications. The Scientific World Journal 2012; 2012: 15.
133. King JE, Eugenin EA, Buckner CM, Berman JW. HIV tat and neurotoxicity. Microbes and Infection 2006; 8: 1347-57.
134. Nakamuta S, Endo H, Higashi Y, Kousaka A, Yamada H, Yano M, et al. Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells. Journal of Neurovirology 2008; 14: 186-95.
135. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhance monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 2006; 27: 123-34.
136. Eugenin EA, Clements JE, Zink MC, Berman JW. Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism. The Journal of Neuroscience 2011; 31: 9456-65.
137. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Annals of neurology 2009; 66: 253-8.
138. Weiss JM, Berman JW. Astrocyte expression of monocyte chemoattractant protein-1 is differentially regulated by transforming growth factor beta. Journal of Neuroimmunology 1998; 91: 190-7.
139. Witwer KW, Gama L, Li M, Bartizal CM, Queen SE, Varrone JJ, et al. Coordinated regulation of SIV replication and immune responses in the CNS. PLoS ONE 2009; 4: e8129.
140. Sahu GK, Paar D, Frost SDW, Smith MM, Weaver S, Cloyd MW. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. Journal of Medical Virology 2009; 81: 9-15.
141. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1-Associated Dementia. PLoS Pathog 2009; 5: e1000395.
142. Le Douce V, Herbein G, Rohr O, Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 2010; 7: 32.
143. Zhu T. HIV-1 in peripheral blood monocytes: an underrated viral source. Journal of Antimicrobial Chemotherapy 2002; 50: 309-11.
144. Centlivre M, Legrand N, Steingrover R, van der Sluis R, Grijsen ML, Bakker M, et al. Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. Journal of Leukocyte Biology 2011; 89: 785-95.
145. Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005; 19: 45-52.
146. Shiramizu B, Ratto-Kim S, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Watt G. HIV DNA and dementia in treatment-naive HIV-1-infected individuals in Bangkok, Thailand. International journal of medical sciences 2007; 4: 13.
147. Kusao I, Shiramizu B, Liang C, Grove J, Agsalda M, Troelstrup D, et al. Cognitive Performance Related to HIV-1-Infected Monocytes. J Neuropsychiatry Clin Neurosci 2012; 24: 71-80.
148. Shiramizu B, Paul R, Williams A, Shikuma C, Watters M, Grove J, et al. HIV Proviral DNA Associated With Decreased Neuropsychological Function. The journal of neuropsychiatry and clinical neurosciences 2007; 19: 157-63.
149. Shiramizu B, Ananworanich J, Chalermchai T, Siangphoe U, Troelstrup D, Shikuma C, et al. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. Journal of Neurovirology 2012; 18: 69-73.
150. Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. Journal of Leukocyte Biology 2003; 74: 635-41.
151. Wang T, Xu Y, Zhu H, Andrus T, Ivanov SB, Pan C, et al. Successful Isolation of Infectious and High Titer Human Monocyte-Derived HIV-1 from Two Subjects with Discontinued Therapy. PLoS ONE 2013; 8: e65071.
152. Shikuma CM, Nakamoto B, Shiramizu B, Liang C-Y, DeGruttola V, Bennett K, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antiviral therapy 2012; 17: 1233-42.
153. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (Hemoglobin Scavenger Receptor) in Normal Tissues, Lymphomas, Carcinomas, and Sarcomas Is Largely Restricted to the Monocyte/Macrophage Lineage. The American Journal of Surgical Pathology 2005; 29: 617-24.
154. Roberts ES, Masliah E, Fox HS. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). Journal of neuropathology and experimental neurology 2004; 63: 1255-64.
155. Kim W-K, Alvarez X, Fisher J, Bronfin B, Westmoreland S, McLaurin J, et al. CD163 Identifies Perivascular Macrophages in Normal and Viral Encephalitic Brains and Potential Precursors to Perivascular Macrophages in Blood. Am J Pathol 2006; 168: 822-34.
156. Borda JT, Alvarez X, Mohan M, Hasegawa A, Bernardino A, Jean S, et al. CD163, a Marker of Perivascular Macrophages, Is Up-Regulated by Microglia in Simian Immunodeficiency Virus Encephalitis after Haptoglobin-Hemoglobin Complex Stimulation and Is Suggestive of Breakdown of the Blood-Brain Barrier. Am J Pathol 2008; 172: 725-37.
157. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro-and antiinflammatory stimuli. Journal of Leukocyte Biology 2000; 67: 97.
158. Shantsila E, Wrigley B, Tapp L, Apostolakis S, Montoro-Garcia S, Drayson MT, et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. Journal of Thrombosis and Haemostasis 2011; 9: 1056-1066.
159. Tippett E, Cheng W-J, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, et al. Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals. PLoS ONE 2011; 6: e19968.
160. Fischer-Smith T, Tedaldi EM, Rappaport J. CD163/CD16 Coexpression by Circulating Monocytes/Macrophages in HIV: Potential Biomarkers for HIV Infection and AIDS Progression. AIDS Research and Human Retroviruses 2008; 24: 417-21.
161. Droste A. Shedding of CD163, a Novel Regulatory Mechanism for a Member of the Scavenger Receptor Cysteine-Rich Family* 1. Biochemical and biophysical research communications 1999; 256: 110.
162. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology 2005; 210: 153-60.
163. Hearps AC, Martin GE, Angelovich TA, Cheng W-J, Maisa A, Landay AL, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012; 11: 867-75.
164. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, Lynch F, et al. Age-Associated Changes in Monocyte and Innate Immune Activation Markers Occur More Rapidly in HIV Infected Women. PLoS ONE 2013; 8: e55279.
165. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 2013; Publish Ahead of Print: 10.1097/QAD.0b013e32836010bd.
166. Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med 2011; 13: e15.
167. Brown A. Osteopontin: A key link between immunity, inflammation and the central nervous system. Translational Neuroscience 2012; 3: 288-93.
168. Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM, Scatena M. Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. Journal of Cellular Biochemistry 2013; 114: 1194-202.
169. Roberts ES, Zandonatti MA, Watry DD, Madden LJ, Henriksen SJ, Taffe MA, et al. Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. The American Journal of Pathology 2003; 162: 2041-57.
170. Burdo TH, Ellis RJ, Fox HS. Osteopontin Is Increased in HIV-Associated Dementia. Journal of Infectious Diseases 2008; 198: 715-22.
171. Brown A, Islam T, Adams R, Nerle S, Kamara M, Eger C, et al. Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals. Journal of Neurovirology 2011; 17: 382-92.
172. Sun J, Feng A, Chen S, Zhang Y, Xie Q, Yang M, et al. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-[bgr]1. Cell Mol Immunol 2013; 10: 176-82.
173. Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. Journal of Leukocyte Biology 2007; 81: 1504-11.
174. Chagan-Yasutan H, Saitoh H, Ashino Y, Arikawa T, Hirashima M, Li S, et al. Persistent Elevation of Plasma Osteopontin Levels in HIV Patients Despite Highly Active Antiretroviral Therapy. The Tohoku Journal of Experimental Medicine 2009; 218: 285-92.
175. Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, et al. HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients. PLoS ONE 2013; 8: e70164.
176. Price RW, Peterson J, Fuchs D, Angel TE, Zetterberg H, Hagberg L, et al. Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. Journal of Neuroimmune Pharmacology 2013: 1-12.
177. Jeon J-W, Park B-C, Jung J-G, Jang Y-S, Shin E-C, Park YW. The Soluble Form of the Cellular Prion Protein Enhances Phagocytic Activity and Cytokine Production by Human Monocytes Via Activation of ERK and NF-B. Immune network 2013; 13: 148-56.
178. Hartmann CA, Martins VR, Lima FRS. High levels of Cellular Prion Protein improve astrocyte development. FEBS Letters 2012.
179. Tomasi V. Signal transduction in neurons: effects of cellular prion protein on fyn kinase and ERK1/2 kinase. Immun Ageing 2010; 7: S5.
180. Moser M, Colello RJ, Pott U, Oesch B. Developmental expression of the prion protein gene in glial cells. Neuron 1995; 14: 509-17.
181. Viegas P, Chaverot N, Enslen H, Perrière N, Couraud P-O, Cazaubon S. Junctional expression of the prion protein PrPC by brain endothelial cells: a role in trans-endothelial migration of human monocytes. Journal of Cell Science 2006; 119: 4634-43.
182. Roberts TK, Eugenin EA, Morgello S, Clements JE, Zink MC, Berman JW. PrPC, the Cellular Isoform of the Human Prion Protein, Is a Novel Biomarker of HIV-Associated Neurocognitive Impairment and Mediates Neuroinflammation. The American Journal of Pathology 2010; 177: 1848-60.
183. Megra B, Eugenin E, Roberts T, Morgello S, Berman J. Protease Resistant Protein Cellular Isoform (PrPc) as a Biomarker: Clues into the Pathogenesis of HAND. Journal of Neuroimmune Pharmacology 2013: 1-8.